Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fentanyl + midazolam is a combination of two pharmaceutical drugs commonly used for procedural sedation and analgesia, particularly in emergency and perioperative settings. Fentanyl is a potent synthetic opioid analgesic that acts primarily as an agonist at the mu-opioid receptor, providing rapid and effective pain relief. Midazolam is a short-acting benzodiazepine that enhances the effect of the neurotransmitter GABA at the GABA(A) receptor, resulting in sedation, anxiolysis, amnesia, and muscle relaxation. When used together intravenously or via other routes under medical supervision, this combination provides synergistic effects for conscious sedation—offering both pain control (from fentanyl) and anxiolysis/amnesia (from midazolam). This allows for lower doses of each drug compared to monotherapy while improving patient comfort during procedures such as endoscopy or orthopedic reductions. The primary risks include respiratory depression due to additive central nervous system depressant effects; therefore, use requires close monitoring by trained personnel with resuscitation equipment available[1][2][3][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fentanyl + midazolam.